ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

KK2430

A development code.

Its studies are mostly in Hematologic Neoplasms, led by Kyowa Kirin.

Furthest: phase 2, since Apr 24, 20261 company-led study, 1 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kyowa Kirin11 open or runningphase 2since Apr 24, 2026Apr 24, 2026Apr 2027phase 2 · NCT07629726

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2026First study: phase 2 study in Hematologic NeoplasmsFirst studyNCT07629726 · 72 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 2 study in Hematologic NeoplasmsNCT07629726

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07629726Hematologic Neoplasms · United States2RecruitingApr 202772

How it is read

Names in the registry

  • “KK2430”, 1 entry

Codes read as this program: KK2430.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.